Loading...
XNAS
QUIT
Market cap697mUSD
Nov 09, Last price  
6.78USD
1D
0.89%
1Q
0.15%
Jan 2017
-99.38%
Name

Achieve Life Sciences Inc

Chart & performance

D1W1MN
XNAS:QUIT chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
80.88%
Shs. 5Y
74.18%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
22,391,85820,130,66320,131,00025,539,00013,616,0005,496,00020,095,00029,882,00027,116,00018,160,0005,062,000000000000
Net income
-55m
L+37.21%
-23,551,296-13,063,168-4,204,0005,476,000-12,584,000-14,673,000-21,098,000-31,849,000-26,240,000-16,801,000-20,129,000-10,583,000-12,687,000-16,395,000-14,661,000-33,152,000-42,350,000-29,815,000-39,827,000-54,648,000
CFO
-49m
L+66.16%
-19,680,553-23,335,332-12,307,00034,878,000-26,840,000-20,263,000-43,493,000-35,927,000-17,308,000-9,101,000-29,683,000-9,107,000-10,623,000-15,216,000-13,474,000-29,440,000-37,569,000-24,479,000-29,770,000-49,465,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.

Key people

Richard Stewart
Chief Executive Officer, Director · since 2024
Mark Oki
Chief Financial and Principal Financial Officer · since 2024
Thomas King
Interim Executive Chairman of the Board · since 2024
Jaime Xinos
Chief Commercial Officer · since 2024
Nancy Phelan
Director · since 2025
Kristen Slaoui
Director · since 2025
Stuart Duty
Independent Director · since 2023
Bridget Martell
Independent Director · since 2021
Thomas Sellig
Independent Director · since 2023
URL
https://achievelifesciences.com/
IPO date
Oct 12, 1995
Employees
20
Domiciled in
US
Incorporated in
US
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
22722 29th Drive Southeast; Suite 100
Bothell, WA 98021
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT